Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials

Robin Pokrzywinski, Robin M Pokrzywinski, Pokrzywinski RM, Ahmed M. Soliman, Jun Chen, Chen J, Michael C. Snabes, Michael Snabes, Snabes M, Diamond MP, Michael P. Diamond, Eric S. Surrey, Eric Surrey, Surrey E, Coyne KS, Karin S. Coyne
Fertility and sterility · 2019 · vol. 112(3) , pp. 545–551 · doi:10.1016/j.fertnstert.2019.04.031 · PMID:31227284 · W2952824795
RCT OA: hybrid CC0 ⤵ 7 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

Elagolix treatment reduced work loss and improved productivity in women with endometriosis-associated pain, leading to estimated cost savings compared to placebo.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To estimate the impact of elagolix on work loss due to endometriosis-associated pain. DESIGN: Post hoc analysis of data from the Elaris I and II clinical trials. SETTING: Not applicable. PATIENT(S): Employed women ages 18-49 years with moderate-to-severe endometriosis-associated pain. INTERVENTION(S): In the two trials, participants were randomized to 6 months of treatment with placebo, elagolix 150 mg once a day, or elagolix 200 mg twice a day. MAIN OUTCOME MEASURE(S): Data on planned work hours, presenteeism, absenteeism, and total work loss (absenteeism + presenteeism) at baseline and month 3 were collected using the Health-Related Productivity Questionnaire. RESULT(S): This analysis included employed participants from EM-I (n = 672) and EM-II (n = 626). Between baseline and month 3, compared with participants treated with placebo, participants treated with elagolix 150 mg once a day gained > 2 hours total work/week (EM-I, 2.20 ± 1.03; EM-II, 2.65 ± 1.14). Participants treated with 200 mg twice a day gained > 4 hours total work/week (EM-I, 4.91 ± 1.04; EM-II, 4.64 ± 1.14). Both absenteeism and presenteeism were reduced, although most of the gain was due to reduced presenteeism. Estimated cost savings after 6 months of treatment with elagolix were > $1,500 U.S. at 150 mg once a day and > $3,300 U.S. at 200 mg twice a day. CONCLUSION(S): Compared with placebo, treating moderate-to-severe endometriosis-associated pain with elagolix reduced absenteeism and improved productivity in employed women, which should result in cost savings. CLINICAL TRIAL NUMBER(S): NCT01620528 (EM-I) and NCT01931670 (EM-II).

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_pain

MeSH descriptors

Absenteeism Absenteeism Endometriosis Endometriosis Hydrocarbons, Fluorinated Pelvic Pain Pelvic Pain Pyrimidines Adolescent Adolescent Adult Adult Endometriosis Endometriosis Endometriosis Female Female Health Surveys Health Surveys Health Surveys

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (16)

Cited by (8)

Source provenance

europepmc
last seen: 2026-10-23T06:08:06.940705+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:24:54.379125+00:00
License: CC0 · commercial use OK